Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200, Showing Anti-Inflammatory Activity Without Cortisol Suppression

Lifordi Immunotherapeutics, Inc. presented first-in-human clinical data for LFD-200, a novel subcutaneously administered antibody-drug conjugate (ADC) delivering a potent glucocorticoid directly to immune cells, at the European Congress of Rheumatology (EULAR) 2026 in London, UK. The Phase 1 study in healthy participants showed that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without impacting serum cortisol levels, a critical marker for systemic glucocorticoid toxicity.

The data, presented in a poster session at EULAR 2026, marks a significant step in the development of ADCs for autoimmune and inflammatory disorders. Unlike traditional glucocorticoid therapies, which can cause systemic side effects such as cortisol suppression, LFD-200 targets delivery of the drug directly to immune cells, potentially reducing off-target effects. According to the company, the favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profile in healthy participants supports continued development in patients with rheumatoid arthritis (RA).

Dosing of patients with moderate to severe RA in the Phase 1 study is ongoing, with data expected by year-end 2026. If successful, LFD-200 could offer a new treatment option for RA and other autoimmune conditions, leveraging the proven success of ADCs in oncology. Lifordi’s approach represents a novel application of ADC technology beyond cancer, targeting inflammatory cells with potent therapeutic payloads.

Lifordi Immunotherapeutics is a clinical-stage biotechnology company focused on developing ADCs for autoimmune and inflammatory diseases. The company has applied its drug delivery platform to other payloads, including antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi aims to transform how immune and inflammatory diseases are treated. For more information, visit www.lifordi.com.

The implications of these findings are substantial for patients with RA and other inflammatory conditions, who often face limited options due to the side effects of systemic glucocorticoids. By demonstrating anti-inflammatory activity without cortisol suppression, LFD-200 could potentially provide a safer alternative that maintains efficacy. The ongoing Phase 1 study in RA patients will be crucial to confirm these benefits in the target population.

As the first-in-human data for LFD-200, the EULAR 2026 presentation provides early evidence of the potential for ADCs in non-oncology indications. If the ongoing study yields positive results, it could pave the way for broader applications of targeted glucocorticoid delivery in autoimmune diseases, addressing a significant unmet medical need.

This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200, Showing Anti-Inflammatory Activity Without Cortisol Suppression.

The post Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200, Showing Anti-Inflammatory Activity Without Cortisol Suppression appeared first on citybuzz.